-+ 0.00%
-+ 0.00%
-+ 0.00%

MicroPort CardioFlow expects H1 2026 revenue at least US$153 million, net loss up to US$25 million

PUBT·08/11/2026 14:13:24
Listen to the news
MicroPort CardioFlow expects H1 2026 revenue at least US$153 million, net loss up to US$25 million
  • MicroPort CardioFlow forecast 1H 2026 revenue of at least USD 153 million.
  • Net loss expected at no more than USD 25 million, reflecting first-time full consolidation of the CRM business acquired Dec. 19, 2025.
  • Pacemaker implant volumes posted double-digit growth in China during the period.
  • VitaFlow Liberty CE-mark commercialization accelerated; non-China implantations rose over 350% in more than 40 countries versus 1H 2025.
  • Integration measures, cost cuts, expense controls aimed at improving efficiency, reducing operating costs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Cardioflow Medtech Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260811-12280599), on August 11, 2026, and is solely responsible for the information contained therein.